Evaluation of the liat cdiff assay for direct detection of clostridioides difficile toxin genes within 20 minutes

Journal of Clinical Microbiology

Volumn 57, Issue 6, 2019, Pages

  Hetem, David J ^a   Bos Sanders, Ingrid ^b   Nijhuis, Roel H T ^a,b   Tamminga, Sven ^a   Berlinger, Livia ^c   Kuijper, Ed J ^b   Sickler, Joanna J ^d   Claas, Eric C J ^b  

^a MEDICAL CENTER HAAGLANDEN   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Bio Analytica AG   (Switzerland)

^d ROCHE MOLECULAR SYSTEMS   (United States)

Author keywords

Clostridioides difficile; GeneXpert; Liat; PCR

Indexed keywords

BACTERIAL TOXIN; BACTERIAL PROTEIN; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ANTIBIOTIC ASSOCIATED DIARRHEA; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; FECES ANALYSIS; FRANCE; GENETIC ANALYSIS; INFECTION CONTROL; LIAT CDIFF ASSAY; NETHERLANDS; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; POINT OF CARE TESTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SWITZERLAND; TURNAROUND TIME; CLOSTRIDIOIDES DIFFICILE; CLOSTRIDIUM INFECTION; GENETICS; HUMAN; MICROBIOLOGY; MOLECULAR DIAGNOSIS; PROCEDURES; RIBOTYPING;

BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; POLYMERASE CHAIN REACTION; RIBOTYPING;

EID: 85066453576     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00416-19     Document Type: Article

References (13)

1. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. 2015. Burden of Clostridium difficile infection in the United States. N Engl J Med 372: 825– 834. https://doi.org/10.1056/NEJMoa1408913.
2. Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. 2016. Clostridium difficile infection. Nat Rev Dis Primers 2:16020. https://doi.org/10.1038/nrdp.2016.20.
3. Zimlichman E, Henderson D, Tamir O, Franz C, Song P, Yamin CK, Keohane C, Denham CR, Bates DW. 2013. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med 173:2039–2046. https://doi.org/10.1001/jamainternmed.2013.9763.
4. Crobach MJT, Baktash A, Duszenko N, Kuijper EJ. 2018. Diagnostic guidance for C. difficile infections. Adv Exp Med Biol 1050:27–44. https://doi .org/10.1007/978-3-319-72799-8_3.
5. Crobach MJT, Vernon JJ, Loo VG, Kong LY, Pechine S, Wilcox MH, Kuijper EJ. 2018. Understanding Clostridium difficile colonization. Clin Microbiol Rev 31:e00021-17. https://doi.org/10.1128/CMR.00021-17.
6. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH. 2018. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 66:e1–e48. https://doi.org/10.1093/cid/cix1085.
7. van den Berg RJ, Kuijper EJ, van Coppenraet LE, Claas EC. 2006. Rapid diagnosis of toxinogenic Clostridium difficile in faecal samples with internally controlled real-time PCR. Clin Microbiol Infect 12:184–186. https://doi.org/10.1111/j.1469-0691.2005.01301.x.
8. Crobach MJT, Duszenko N, Terveer EM, Verduin CM, Kuijper EJ. 2018. Nucleic acid amplification test quantitation as predictor of toxin presence in Clostridium difficile infection. J Clin Microbiol 56:e01316-17. https://doi.org/10.1128/JCM.01316-17.
9. Sewell B, Rees E, Thomas I, Ch’ng CL, Isaac M, Berry N. 2014. Cost and impact on patient length of stay of rapid molecular testing for Clostridium difficile. Infect Dis Ther 3:281–293. https://doi.org/10.1007/s40121-014-0034-x.
10. Egilmezer E, Walker GJ, Bakthavathsalam P, Peterson JR, Gooding JJ, Raw-linson W, Stelzer-Braid S. 2018. Systematic review of the impact of point-of-care testing for influenza on the outcomes of patients with acute respiratory tract infection. Rev Med Virol 28:e1995. https://doi.org/10.1002/rmv.1995.
11. Garg SK, Lu K, Duncan J, Peterson LR, Liesenfeld O. 2017. Equivalent performance of the Cobas® Cdiff test for use on the Cobas® Liat® system and the Cobas® 4800 system. Eur J Microbiol Immunol (Bp) 7:310–318. https://doi.org/10.1556/1886.2017.00034.
12. van den Berg RJ, Claas EC, Oyib DH, Klaassen CH, Dijkshoorn L, Brazier JS, Kuijper EJ. 2004. Characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping. J Clin Microbiol 42:1035–1041. https://doi.org/10.1128/JCM.42.3.1035-1041.2004.
13. Granato PA, Hansen G, Herding E, Chaudhuri S, Tang S, Garg SK, Rowell CR, Sickler JJ. 2018. Performance comparison of the cobas Liat and Cepheid GeneXpert systems for Clostridium difficile detection. PLoS One 13:e0200498. https://doi.org/10.1371/journal.pone.0200498.